In an interview conducted during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021, Maria-Victoria Mateos, MD, PhD, Associate Professor of Medicine, University of Salamanca, Salamanca, Spain discusses treatment for patients with newly diagnosed, transplant-ineligible multiple myeloma. The addition of monoclonal antibodies to the current standard of care, which consists of bortezomib, melphalan, and prednisone (VMP) or bortezomib, lenalidomide, and dexamethasone (VRd), has been shown to increase progression-free and overall survival, particularly among elderly and frail patients. Dr Mateos describes data from the Phase III MAIA trial, which was designed to investigate the combination of daratumumab with lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma.